logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – The value of adding bevacizumab to carboplatin/pegylated liposomal doxorubicin when treating recurrent ovarian cancer

A new combination regimen based on the three drugs has been shown to provide a significant benefit in progression-free survival compared to standard combination regimens